Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Ratio (2016 - 2026)

Insight Molecular Diagnostics' Equity Ratio history spans 7 years, with the latest figure at 1.22 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 249.16% to 1.22 in Q4 2025 year-over-year; TTM through Dec 2025 was 1.22, a 249.16% decrease, with the full-year FY2025 number at 1.22, down 249.16% from a year prior.
  • Equity Ratio hit 1.22 in Q4 2025 for Insight Molecular Diagnostics, down from 0.21 in the prior quarter.
  • Over the last five years, Equity Ratio for IMDX hit a ceiling of 0.82 in Q1 2021 and a floor of 1.22 in Q4 2025.
  • Historically, Equity Ratio has averaged 0.24 across 5 years, with a median of 0.37 in 2022.
  • Biggest five-year swings in Equity Ratio: surged 33.97% in 2021 and later crashed 251.34% in 2025.
  • Tracing IMDX's Equity Ratio over 5 years: stood at 0.41 in 2021, then dropped by 16.18% to 0.34 in 2022, then decreased by 20.23% to 0.27 in 2023, then crashed by 228.02% to 0.35 in 2024, then plummeted by 249.16% to 1.22 in 2025.
  • Business Quant data shows Equity Ratio for IMDX at 1.22 in Q4 2025, 0.21 in Q3 2025, and 0.02 in Q2 2025.